Zynlonta ® (loncastuximab tesirine-lpyl) developed by ADC Therapeutics is a CD19-directed ADC indicated for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified DLBCL arising from low grade lymphoma ...

Apr 23, 2021 · ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents.

Aug 15, 2024 · Here, we describe the preclinical characterization of ABBV-319, a CD19-targeting glucocorticoid receptor modulator (GRM) agonist, antibody-drug conjugate (ADC), for the treatment of B-cell malignancy.

Mar 8, 2018 · ADCT-402 (loncastuximab tesirine) is a novel CD19-targeted ADC delivering SG3199, a highly cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PDB) dimer warhead. It showed potent and highly targeted in vitro cytotoxicity in CD19-expressing human cell lines.

Feb 3, 2020 · Loncastuximab tesirine (also known as ADCT-402) is an ADC comprising a humanized anti-CD19 antibody, stochastically conjugated through a cathepsin-cleavable valine-alanine linker to SG3199, a pyrrolobenzodiazepine (PBD) dimer toxin.

CD19 has a broader expression profile than that of CD20 and it is thought to be a better target for antibody-drug conjugates (ADC) compared with CD20, which suffers from inefficient internalization.

In this study we have shown that: (i) the CD19-targeting ADC loncastuximab tesirine has strong cytotoxic activity in a large panel of cell lines derived from B-cell lymphomas; (ii) its in vitro activity correlated with the level of CD19 expression; and (iii) there is benefit of adding loncastuximab tesirine to other agents, especially BCL2 and ...

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development.

Apr 23, 2021 · ADC Therapeutics scored an FDA nod for Zynlonta, formerly known as loncastuximab, as a solo treatment for adult patients with relapsed or refractory DLBCL after two prior lines of therapy.

Mar 31, 2025 · To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual targeted lentiviral anti-CD20/anti-CD19 (LV20.19) CAR T cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: NCT04186520).